(VIANEWS) – FibroGen (NASDAQ: FGEN) saw its share price decrease dramatically, falling 34.78% over 21 trading sessions. After opening at EUR0.92, shares opened on September 14th and closed at EUR0.60 two consecutive trading days later following two days of losses – this decline coincided with an overall decrease of 1.23% for the NASDAQ index to EUR13,407.23, leaving FibroGen’s closing price 97.59% off of its 52-week high of EUR25.69.
About FibroGen
FibroGen Pharmaceuticals Inc is a biopharmaceutical company committed to discovering, developing and commercializing innovative therapeutics to address unmet medical needs. Their lead product candidates – Pamrevlumab and Roxadustat – are in various stages of clinical development for treating idiopathic pulmonary fibrosis, pancreatic cancer, Duchenne muscular dystrophy anemia related to chronic kidney disease as well as myelodysplastic syndromes. With collaboration agreements in place with Astellas Pharma Inc and AstraZeneca AB the company was established back in 1993 based out of San Francisco California.
Yearly Analysis
FibroGen’s stock is currently trading below its 52-week low, which could be seen as a warning signal for investors. However, anticipated sales growth rates of 10.1% and 9.5% for this and next years are relatively strong and bode well for growth within this company.
FibroGen’s EBITDA stands at an insufficient 0.05, suggesting it may not yet be profitable. Nonetheless, its sales growth projections show evidence of investing in its business to support future expansion; which could be seen as positive sign for investors if its strategy succeeds in actualising itself.
FibroGen may present investors with a high degree of risk due to its current valuation and low EBITDA, yet its projected sales growth could make it attractive to investors with an appetite for risk. Therefore, investors should thoroughly research all available information before consulting with a financial advisor before making any definitive investment decisions.
Technical Analysis
FibroGen stock has seen a substantial decrease in value recently, falling far below both its 50-day and 200-day moving averages. Furthermore, its last reported volume (1230131) indicates a lack of investor enthusiasm in investing.
FibroGen’s volatility has seen a notable reduction in recent months and quarters, with its average intraday variation at negative 2.25% and its maximum intraday variation average at negative 1.42% respectively. Yet its amplitude of average volatility remains elevated, recording its highest weekly peak amplitude as 8.73% last week.
Stochastic oscillator data indicates that FibroGen’s stock may currently be considered “overbought”, with readings above 80 suggesting a possible correction or decline in value in the near future.
Overall, FibroGen stock appears to be experiencing a bearish trend with low moving averages, low volume, and overbought status. Investors should exercise extreme caution and carefully monitor its performance prior to making any investment decisions.
Quarter Analysis
FibroGen, a biotechnology company, experienced remarkable sales growth this quarter of 134.1% and anticipates future expansion by 13.7% in its next quarter. Current and next quarter estimates for growth estimates stand at 30.6% and 47.1%, respectively.
FibroGen has experienced rapid revenue growth with year-on-year quarterly revenue increases of 48.7% and totaling 130.58M for twelve trailing months, making them an attractive option for investors looking for strong revenue growth potential companies.
However, investors must bear in mind that FibroGen operates in an extremely competitive industry that can be unpredictable. Therefore, investors should conduct thorough research and analysis prior to making any investment decisions regarding FibroGen – including financial health indicators, pipeline products, competition landscape, market trends and general company strategy.
Equity Analysis
FibroGen’s trailing twelve months EPS stands at EUR-2.66, indicating it experienced losses per share over the past year and investors should exercise caution when investing in such companies with negative earnings.
Additionally, the company’s return on equity (ROE) for the last twelve trailing months was negative -1015.79%, suggesting it has not generated profits for shareholders relative to their equity investment in the company. A negative ROE can be an indicator that indicates inefficient utilization of assets by management for making profits and is thus an early warning signal.
Investors should thoroughly assess FibroGen’s financial performance, such as profitability and return on equity before making any investment decisions.
More news about FibroGen (FGEN).
